HR 1843
119th Congress
House
Health
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 5, 2025
Referred to the House Committee on Energy and Commerce.
Mar 5, 2025
Introduced in House
Plain-English summary
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
What's happening now
Referred to the House Committee on Energy and Commerce.
Committees of jurisdiction
1
Cosponsors
1